How do we manage t(11;14) plasma cell disorders with venetoclax?
Rajshekhar Chakraborty, Divaya Bhutani, Suzanne Lentzsch
Abstract
The oral BCL-2 inhibitor venetoclax has demonstrated promising efficacy in patients with t(11;14) plasma cell disorders, both as a single-agent and in combination. However, there was an increased mortality signal in the randomized BELLINI trial that was primarily driven by non-t(11;14) patients. Based on current evidence, venetoclax is included as an option for relapsed/refractory t(11;14) plasma cell dyscrasias in NCCN guidelines and is being widely used in clinical practice. In this review, we aim to critically appraise the current literature and perform case-based illustration of our approach to management of t(11;14) plasma cell disorders with venetoclax.
Topics & Concepts
VenetoclaxDyscrasiaMedicinePlasma cellClinical PracticeIntensive care medicineOncologyInternal medicineFamily medicineLeukemiaBone marrowChronic lymphocytic leukemiaMultiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia ResearchPI3K/AKT/mTOR signaling in cancer